Since 2002, Dr. John Maraganore has served as the CEO and a Director of Alnylam.
Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases. He was previously Vice President, Strategic Planning and M&A and, prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company.
Dr. Maraganore received his Master of Science and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is a member of the Board for Agios Pharmaceuticals and Biotechnology Industry Organization (BIO) Board and is a member of the BIO Executive Committee.
Dr. Yvonne Greenstreet joined Alnylam in 2016 as Chief Operating Officer and was promoted to President and COO in 2020. Yvonne has more than 25 years of experience in the Biopharmaceutical industry, driving strategy and innovation, bringing transformative medicines to patients, and building successful businesses in the US, Europe and globally.
Between 2011 and 2013, Yvonne was Senior Vice President and Head of Medicines Development at Pfizer serving on the executive team leading a rapidly growing $16bn division. Prior to Pfizer, she was at GlaxoSmithKline plc for 18 years, where she was Senior Vice President and Chief of Strategy for Research and Development. Yvonne had previously been in various positions of increasing responsibility at GSK, including Senior Vice President for Medicines Development and Chief Medical Officer for Europe.
Yvonne trained as a physician and earned her medical degree (MBChB) from The University of Leeds in the UK. She also holds an MBA from INSEAD Business school in France. Dr. Greenstreet serves on the board of directors of Pacira Pharmaceuticals and American Funds. Additionally, she is in the Scientific Advisory Committee of the Bill and Melinda Gates Foundation and is a member of the Discovery Council of Harvard Medical School.
Dr. Pushkal Garg joined Alnylam in 2014 with 15 years of experience in clinical drug development. He oversees all clinical development activities at Alnylam.
Prior to joining Alnylam, Dr. Garg served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). He was the strategic leader of the Immunoscience franchise and oversaw the development of multiple clinical assets across the areas of rheumatology, gastroenterology, nephrology, and transplantation. While at BMS, he was instrumental to the late-stage development and approval of Nulojix® (belatacept) for kidney transplant recipients, and for supplementary biologics license applications (BLAs) for Orencia® (abatacept). Preceding this, Dr. Garg held various roles at Millennium Pharmaceuticals, overseeing the clinical development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders.
Dr. Garg received a Bachelor of Arts with high honors in Biochemistry from the University of California, Berkeley, and his M.D. from the University of California, San Francisco. He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women’s Hospital in Boston prior to joining the industry. Dr. Garg is a member of the Board of Directors of SQZ Biotechnologies (SQZ).
Jeff Poulton joined Alnylam as CFO in August 2019. Prior to joining Alnylam, Jeff served as Chief Financial Officer at Indigo Agriculture, a plant microbiome company, from January 2018 to April 2019, where he supported the initial commercial scale-up of the business, including expansion outside the US.
Between 2003 and December 2017, Jeff held various roles of increasing responsibility at Shire Plc, culminating in his service as Chief Financial Officer and a member of Shire’s Executive Committee and Board of Directors from January 2015 to December 2017. During his tenure at Shire, Jeff also led Shire’s rare disease US, LATAM, and Asia Pacific commercial operations, as well as Shire’s global rare disease business unit. Prior to Shire, Jeff led corporate finance and business development initiatives in both the gas and electric utilities industry and the materials manufacturing sector, serving in financial leadership positions at Cinergy Corp and PPG Industries. Jeff also served in the United States Navy as a Commissioned Officer.
Jeff holds a BA in Economics from Duke University and an MBA in Finance from the Kelley School of Business at Indiana University. He is a member of the Board of Directors of EIP Pharmaceuticals and Homology Medicines.
Dr. Akshay Vaishnaw joined Alnylam Pharmaceuticals in 2006 as VP Clinical Research and has then subsequently served in various R&D roles with increasing responsibility. Akshay is currently the President of R&D. Prior to 2006, he was at Biogen as Senior Director, Translational Medicine.
Akshay received his M.D. from the University of Wales College of Medicine, U.K., and Ph.D. from the University of London, U.K., in Molecular Immunology. He is a Fellow of the Royal College of Physicians, U.K. Akshay is a member of the Board of Directors for Editas Medicine Inc. and Scholar Rock Inc. From 2014-2018, he served as a Board member of Visterra, Inc.
Kelley Boucher joined Alnylam in 2019 bringing nearly 20 years of experience within the biotechnology and medical device industries. She oversees the global HR organization which includes talent planning & strategy, organizational effectiveness, talent acquisition, learning & development, total rewards, and HR systems.
Prior to Alnylam, Kelley served as Vice President and Global Head of Human Resources at Abiomed for three years as the company experienced exponential growth and commercial execution. Before her time at Abiomed, Kelley spent 10 years at Shire where she held a variety of roles across HR, eventually becoming Vice President and Head of Human Resources for Technical Operations and then Shire’s Corporate Divisions. She also managed the organizational design component of multiple acquisitions. Prior to Shire, Kelley was a Principal Consultant at Clockwork Consulting (a pharmaceutical recruitment firm) and worked at Syntonix Pharmaceuticals (acquired by Biogen) and Digitas. She was honored with the Healthcare Business Women’s Association Rising Star award in 2013. Kelley is a member of the Healthcare Business Women’s Association (HBA), the Human Resources Leadership Forum (HRLF) and the Corporate Executive Board (CEB).
Kelley attended Cornell University where she received her Bachelor of Arts in government relations and the Darden School of Business at the University of Virginia where she completed her studies in the Strategic Leadership Development executive program.
Dr. Alfred “Al” Boyle joined Alnylam in 2015 with over 20 years of experience within the biotechnology, pharmaceutical and chemical industries. He leads a team accountable for all aspects of CMC development, clinical and commercial product manufacturing and supply, enterprise GxP Quality oversight and facilities and engineering operations globally.
Prior to joining Alnylam, Al served as Vice President of Global Technical Services at Alexion Pharmaceuticals where he was responsible for technology transfer and process oversight of cGMP manufacturing of clinical and commercial products. Prior to this role, Al served as Vice President, Technical Operations in Switzerland and Ireland also with Alexion. For this position, he led an organization in Switzerland accountable for business, technical and quality oversight of drug substance, drug product and finished product contract manufacturing organizations; and led the relocation of this organization to Ireland. Prior to Alexion, Al spent over eight years with Bristol-Myers Squibb, overseeing fermentation and biocatalysis development, technology transfer and commercial manufacturing support of biologics products. He also held positions in the Research and Development functions of Celgene Corporation, Akzo-Nobel and Hercules Inc.
Dr. Boyle obtained his Bachelor of Science and Master of Science degrees from the State University of New York College of Environmental Science and Forestry and a Ph.D. in Microbiology from Rutgers University.
Tolga Tanguler joined Alnylam in January 2021 and has over 20 years of global biopharmaceutical experience in a variety of marketing and commercial roles. He has worked across multiple geographies including the U.S, Europe, and emerging markets and in a broad range of small and large disease therapy areas.
Prior to joining Alnylam, Tolga served for two years as Senior Vice President and Head of Alexion U.S., where he led an organization of 700 colleagues across sales, market access, marketing, operations, and patient services. Before Alexion, he spent the majority of his career at Pfizer serving in roles of increasing responsibility, most recently as Regional President, North America for Rare Diseases and prior to that as Global Vice President and Alliance Co-Head, Eliquis, as well as and serving as a country manager of Denmark and Iceland during his tenure.
Tolga received his Bachelor of Science in Finance and Economics from Istanbul University in Turkey and his MBA in Marketing and Supply Chain Management from Michigan State University, as well as a post graduate certificate in Marketing from the University of California, Santa Barbara.
Aggie Gallagher joined Alnylam in 2020 as SVP Chief Compliance Officer and was promoted to the Management Board as Chief Ethics and Compliance Officer in 2021. Aggie has more than 20 years of diverse international experience in the global biopharmaceutical and life sciences industries establishing legal, compliance and risk management infrastructures.
Prior to joining Alnylam, Aggie served as General Counsel, Chief Compliance Officer & Company Secretary at ViiV Healthcare, where she oversaw multiple global launches and restructured the legal and compliance departments to better align with operations and enable delivery of the business strategy. Before ViiV, Aggie held various legal and compliance leadership roles at GSK in Belgium, Sandoz in Germany and Pfizer in the U.S. and multiple international locations where she led high-performing global teams, vastly improved legal and compliance functions, contributed to commercial objectives, and adeptly managed risk.
Aggie holds a Doctor of Jurisprudence from Rutgers Law School, a Bachelor of Arts in political science and Spanish from Rutgers College, and is certified as a Leading Professional in Ethics and Compliance.
The Alnylam Board of Directors is composed of accomplished leaders from the healthcare industry who bring their experience in science, drug development, commercialization, and strategy to our efforts in developing RNAi (RNA interference) therapeutics.
Former Board Chair, Executive Chair and Chief Executive Officer of Kaleido Biosciences; former Board Chair of Magenta Therapeutics; former Director of Bristol Myers Squibb Company, Sarepta Therapeutics and Syros Pharmaceuticals, and former Chief Executive Officer and Director of Cubist Pharmaceuticals.
Director of the Center for Assessment Technology and Continuous Health (CATCH); Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School; Physician‐in‐Chief Emeritus at Massachusetts General Hospital; Member of the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Sciences; Director of Seres Therapeutics and Rani Therapeutics.
Senior Advisor at Blackstone Group, former Chief Executive Officer and Director of Sanofi, former Chief Executive Officer and Chair of Bayer HealthCare, former President and General Manager of the Emerging Markets and Established Products business units, and member of the Executive Leadership Team of Pfizer Inc.
Former Chief Financial Officer of Millennium Pharmaceuticals; Chair of the Board of Directors of Cyclerion Therapeutics; Director of Syros Pharmaceuticals and Forma Therapeutics.
Former Commissioner of the U.S. Food & Drug Administration (FDA); Interim Vice President, Global Biological Policy and Programs at the Nuclear Threat Initiative; former Foreign Secretary of the National Academy of Medicine (NAM); and former Chair of the Board of the American Association for the Advancement of Science (AAAS).
Chief Executive Officer of Alnylam; Member of the Board of Directors of Agios Pharmaceuticals; Member and former Chair of the Biotechnology Industry Organization (BIO).
Chairman of the Board, President and Chief Executive Officer of Karuna Therapeutics and board member of Voyager Therapeutics, Inc.; Venture Partner at Third Rock Ventures; co-founder and board member of SAGE Therapeutics; trustee for the Foundation for the National Institute of Mental Health (NIH); former President of the Lilly Research Laboratories of Eli Lilly and Company; former Scientific Director of the National Institute of Mental Health and adjunct professor of Psychiatry at Washington University of St. Louis School of Medicine.
Former Chair and Chief Executive Officer of Allergan; Member of the Supervisory Board of Royal Philips in the Netherlands; Director of BioMarin Pharmaceutical and Pliant Therapeutics, former Lead Director of Avery Dennison Corporation.
Former President of Plan Operations and Chief Operating Officer of Health Care Service Corporation (HCSC); former President and Chief Operating Officer of Blue Cross Blue Shield of Minnesota. Director of Myriad Genetics and Cricket Health.
Managing Partner, Polaris Partners; Co-founder, Executive Chair, and former Chief Executive Officer of Lyndra Therapeutics; Executive Chair of SQZ Biotech; Senior Lecturer at Harvard Business School; former Executive Vice President and General Counsel of Pfizer; served as the Business Unit Lead for Pfizer Consumer Healthcare.
Institute Professor, The Koch Institute for Integrative Cancer Research, MIT; Founding Director of McGovern Institute for Brain Research, MIT; Nobel Laureate; Founder of Alnylam; Co-founder and former Director of Biogen; Member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences; Director of Syros Pharmaceuticals and Vir Biotechnology.